Pharmaceutical and Healthcare Industry in Ukraine

The pharmaceutical and healthcare industry in Ukraine is showing signs of improvement, despite the ongoing COVID-19 pandemic. With the approval of multiple vaccines, including the Johnson & Johnson, Pfizer, and AstraZeneca vaccines, it is expected that the increasing vaccination of the population will help control the spread of the outbreak. The industry is expected to see growth in the coming years, driven by increased pharmaceutical and healthcare spending, and demand for COVID-19 related vaccines and services.

Key Takeaways:

The Ukrainian pharmaceutical industry is expected to grow in the coming years, driven by increased pharmaceutical and healthcare spending.
The industry is expected to see growth in the segments of prescription drugs, generic drugs, and OTC medicines.
Ukraine's adoption of new healthcare reform bills in 2018 has improved the overall outlook for the healthcare and pharmaceutical industry.
Ukrainian companies, such as Farmak International and Arterium Corporation, are emerging as leading industry players.
The report covers in-depth analysis of the regulatory framework governing the Ukrainian pharmaceutical and healthcare industry.
Major domestic and multinational players in the industry include Farmak, Arterium Corporation, AstraZeneca, Eli Lilly, Glaxo Smith Kline, Johnson & Johnson, and Merck & Co.

Statistics:

Ukraine is one of the largest pharmaceutical markets in the Central and Eastern European region.
The country's pharmaceutical industry is expected to grow at a CAGR of 5.5% from 2021 to 2025.
Prescription drugs market in Ukraine is expected to reach USD 1.3 billion by 2025.
The generic drugs market in Ukraine is expected to reach USD 450 million by 2025.
The OTC medicines market in Ukraine is expected to reach USD 300 million by 2025.

Sources:

ResearchAndMarkets.com.[1]
Businesswire.com.[2]

Note:

[1] https://www.researchandmarkets.com/r/u8apba

[2] https://www.businesswire.com/news/home/20210720005504/en/